Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 532 Thousand EUR | -75.23% |
| 2022 | 2.14 Million EUR | 53.54% |
| 2021 | 1.39 Million EUR | 74.88% |
| 2020 | 800 Thousand EUR | 44.4% |
| 2019 | 554 Thousand EUR | 16.88% |
| 2018 | 474 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 104 Thousand EUR | 152.53% |
| 2024 Q2 | 104 Thousand EUR | 0.0% |
| 2023 Q1 | 464 Thousand EUR | -21.69% |
| 2023 FY | 532 Thousand EUR | -75.23% |
| 2023 Q4 | -198 Thousand EUR | 7.48% |
| 2023 Q3 | -214 Thousand EUR | -146.12% |
| 2023 Q2 | 464 Thousand EUR | 0.0% |
| 2022 Q1 | 481.5 Thousand EUR | 18.45% |
| 2022 Q3 | 592.5 Thousand EUR | 23.05% |
| 2022 Q4 | 592.5 Thousand EUR | 0.0% |
| 2022 Q2 | 481.5 Thousand EUR | 0.0% |
| 2022 FY | 2.14 Million EUR | 53.54% |
| 2021 Q1 | 293 Thousand EUR | -0.51% |
| 2021 FY | 1.39 Million EUR | 74.88% |
| 2021 Q4 | 406.5 Thousand EUR | 0.0% |
| 2021 Q3 | 406.5 Thousand EUR | 38.74% |
| 2021 Q2 | 293 Thousand EUR | 0.0% |
| 2020 Q2 | 105.5 Thousand EUR | 0.0% |
| 2020 Q3 | 294.5 Thousand EUR | 179.15% |
| 2020 Q1 | 105.5 Thousand EUR | 0.0% |
| 2020 FY | 800 Thousand EUR | 44.4% |
| 2020 Q4 | 294.5 Thousand EUR | 0.0% |
| 2019 FY | 554 Thousand EUR | 16.88% |
| 2018 FY | 474 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 88.534% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 88.487% |
| Adocia SA | 2.15 Million EUR | 75.256% |
| Aelis Farma SA | 9.05 Million EUR | 94.124% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 83.116% |
| genOway Société anonyme | 20.04 Million EUR | 97.346% |
| IntegraGen SA | 12.53 Million EUR | 95.757% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -77.313% |
| Neovacs S.A. | 533.41 Thousand EUR | 0.265% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 68.362% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -2587.412% |
| Sensorion SA | 4.74 Million EUR | 88.784% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -79.529% |
| TME Pharma N.V. | 17 Thousand EUR | -3029.412% |
| Valbiotis SA | 4.73 Million EUR | 88.76% |
| TheraVet SA | 1.07 Million EUR | 50.652% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 70.444% |
| argenx SE | 1.13 Billion EUR | 99.953% |
| BioSenic S.A. | 543 Thousand EUR | 2.026% |
| Celyad Oncology SA | 102 Thousand EUR | -421.569% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.778% |
| Genfit S.A. | 28.56 Million EUR | 98.138% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 74.509% |
| Innate Pharma S.A. | 51.9 Million EUR | 98.975% |
| Inventiva S.A. | 17.47 Million EUR | 96.956% |
| MaaT Pharma SA | 2.22 Million EUR | 76.122% |
| MedinCell S.A. | 9.16 Million EUR | 94.192% |
| Nanobiotix S.A. | 30.05 Million EUR | 98.23% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 96.251% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 76.111% |
| Oxurion NV | 263 Thousand EUR | -102.281% |
| Pharming Group N.V. | 245.31 Million EUR | 99.783% |
| Poxel S.A. | 1.98 Million EUR | 73.145% |
| GenSight Biologics S.A. | 1.26 Million EUR | 58.011% |
| Transgene SA | 1.18 Million EUR | 55.068% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.99% |
| Valneva SE | 153.71 Million EUR | 99.654% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 114.696% |